NEW YORK (AP) -- Drug developer Simcere Pharmaceutical Group said Wednesday it suspended production at its Jiangsu Yanshen Biological Technology Stock Co. unit to conduct an internal inspection following the discovery of quality control problems.
Simcere said it discovered quality control issues at the unit after obtaining a controlling stake in October. Specifically, there were problems with the production of Yanshen's human-use rabies vaccine.
American Depository Shares of the China-based drug developer closed at $8.03 Tuesday.
